<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial management of pemphigus vulgaris and pemphigus foliaceus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial management of pemphigus vulgaris and pemphigus foliaceus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial management of pemphigus vulgaris and pemphigus foliaceus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Hertl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shamir Geller, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John J Zone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H73755013"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "pemphigus" describes a group of autoimmune, mucocutaneous, blistering disorders characterized by acantholysis (loss of keratinocyte-to-keratinocyte adhesion) in the epithelium of mucous membranes or skin. Pemphigus vulgaris (<a class="graphic graphic_picture graphicRef57924 graphicRef53425 graphicRef51868 graphicRef63170" href="/d/graphic/57924.html" rel="external">picture 1A-D</a>) and pemphigus foliaceus (<a class="graphic graphic_picture graphicRef60530 graphicRef72419" href="/d/graphic/60530.html" rel="external">picture 2A-B</a>) are the two most common forms of pemphigus. Significant morbidity and mortality can occur as a result of complications of these diseases and their treatments.</p><p>Systemic glucocorticoids and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> are the mainstays of therapy for pemphigus vulgaris and pemphigus foliaceus and are usually highly effective for obtaining control of disease (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Other immunomodulatory agents, such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, are commonly prescribed in conjunction with systemic glucocorticoids in an attempt to minimize the risk for adverse effects of long-term, high-dose glucocorticoid therapy. Interventions such as intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), immunoadsorption, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> are typically reserved for patients with refractory disease. (See  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p>The initial management of pemphigus vulgaris and pemphigus foliaceus will be reviewed here. The management of refractory pemphigus vulgaris and pemphigus foliaceus, the pathogenesis and diagnosis of pemphigus, and the diagnosis and management of paraneoplastic pemphigus and fogo selvagem (endemic pemphigus foliaceus) are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/110145.html" rel="external">"Fogo selvagem (Brazilian endemic pemphigus foliaceus)"</a>.)</p><p></p><p class="headingAnchor" id="H73755020"><span class="h1">RATIONALE FOR TREATMENT</span><span class="headingEndMark"> — </span>Although pemphigus vulgaris typically presents as a more severe disorder than pemphigus foliaceus due to the frequent presence of both mucosal and cutaneous involvement, both disorders can lead to significant morbidity:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral mucosal involvement, which occurs in almost all patients with pemphigus vulgaris, is usually accompanied by severe pain and may lead to poor alimentation, resulting in weight loss and malnutrition (<a class="graphic graphic_picture graphicRef56333 graphicRef57924 graphicRef77462" href="/d/graphic/56333.html" rel="external">picture 1A, 1E-F</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The widespread loss of the epidermal barrier in pemphigus vulgaris and pemphigus foliaceus may lead to protein loss, fluid loss, electrolyte imbalances, dietary insufficiencies, increased catabolism, and increased risk for local and systemic infections (<a class="graphic graphic_picture graphicRef53425 graphicRef51868 graphicRef63170 graphicRef74842" href="/d/graphic/53425.html" rel="external">picture 1B-D, 1G</a>). (See  <a class="medical medical_review" href="/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Clinical features'</a>.)</p><p></p><p>The complications of pemphigus vulgaris can be life threatening. It is estimated that prior to the use of systemic immunosuppressants, more than 70 percent to nearly 100 percent of patients died within one to five years [<a href="#rid1">1-3</a>]. Pemphigus foliaceus, which is characterized by shallow blisters and involvement limited to the skin, is considered to have a better prognosis than pemphigus vulgaris (<a class="graphic graphic_picture graphicRef54341 graphicRef60530 graphicRef72419" href="/d/graphic/54341.html" rel="external">picture 2A-C</a>) [<a href="#rid3">3</a>]. However, progression of pemphigus foliaceus may lead to extensive involvement and similar complications.</p><p class="headingAnchor" id="H2230193340"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>The initial goal of treatment in pemphigus is to induce complete remission while minimizing treatment-related adverse effects. Long-term remission after the discontinuation of therapy is the ultimate goal for patient management, although it may take some time to achieve:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom and when to treat </strong>– Given the potential for severe morbidity and mortality from pemphigus vulgaris and pemphigus foliaceus, treatment is always indicated at the time of disease onset, even for patients who initially present with mild disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions </strong>– Treatment must be approached carefully because the therapeutic regimens for pemphigus are not benign. Most of the estimated 5 to 10 percent mortality rate from pemphigus vulgaris is considered to result from complications from treatment [<a href="#rid4">4-7</a>]. Infections, ranging from minor skin infections to life-threatening, opportunistic infections, are common complications of the immunosuppressive regimens typically used for pemphigus therapy [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach </strong>– The paucity of large, high-quality, prospective trials that compare treatments for pemphigus and the variability in study protocols, outcome measures, and results have made definitive conclusions on the best approach to treatment difficult [<a href="#rid10">10</a>]. Adherence to the definitions for patient assessment outlined by a 2008 consensus of experts may facilitate systematic interpretation of published literature in the future [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">In general, a similar therapeutic approach is taken for pemphigus vulgaris and pemphigus foliaceus (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Many studies that have evaluated therapies for pemphigus have combined patients with these disorders [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Attaining disease control </strong>– The first priority for patient management is to attain rapid disease control. This is typically achieved through the administration of systemic glucocorticoids or a combination of systemic glucocorticoids and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid13">13-15</a>]. (See <a class="local">'Selection of primary therapy'</a> below and <a class="local">'Rituximab and systemic glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incorporating adjuvant immunosuppressive therapy </strong>– Although systemic glucocorticoid therapy is effective, the high doses and long treatment periods that are needed to maintain the clinical response may lead to serious or life-threatening side effects [<a href="#rid4">4</a>]. Thus, for patients who are not receiving <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, adjuvant immunosuppressants (<a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) are typically prescribed at the start of systemic glucocorticoid therapy or shortly thereafter, with the goal of reducing dependence on systemic glucocorticoid therapy. (See <a class="local">'Systemic glucocorticoids and adjuvant immunosuppressive therapy'</a> below and <a class="local">'Adjuvant conventional immunosuppressive therapies'</a> below.)</p><p></p><p class="bulletIndent2">Additional adjuvant therapies typically reserved for refractory pemphigus are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tapering and cessation of therapy following achievement of disease control </strong>– Following achievement of disease control, therapy is reduced slowly to the lowest dose that is necessary to prevent the appearance of new lesions. For patients on systemic glucocorticoids and adjuvant immunomodulatory therapy, the systemic glucocorticoid is typically tapered and discontinued prior to the tapering of adjuvant therapy. (See <a class="local">'Assessing the response to therapy'</a> below and <a class="local">'After achievement of disease control'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptom management </strong>– Measures aimed at managing oral pain and cutaneous wounds are additional, important aspects of the management of pemphigus [<a href="#rid1">1</a>]. Such measures may help to improve patient quality of life and prevent and manage secondary infection. (See <a class="local">'Supportive care'</a> below.)</p><p></p><p class="headingAnchor" id="H276142720"><span class="h1">ASSESSING THE RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>Patients with pemphigus should be followed closely to evaluate disease activity and the response to treatment, as well as to assess for adverse effects of therapy. Because pemphigus is a dynamic disease, management often requires frequent adjustments of therapy [<a href="#rid1">1</a>].</p><p>The response to treatment is primarily assessed through clinical observation. Features that indicate control of disease activity include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cessation of new blister formation</p><p class="bulletIndent1"><span class="glyph">●</span>Established lesions begin to heal</p><p class="bulletIndent1"><span class="glyph">●</span>Absent Nikolsky sign (<a class="graphic graphic_picture graphicRef78514" href="/d/graphic/78514.html" rel="external">picture 3</a>)</p><p></p><p>Complete remission (on or off therapy) is considered the absence of new or established lesions. Complete remission off therapy is considered the absence of new and/or established lesions for at least two months after stopping systemic therapy [<a href="#rid14">14</a>].</p><p>Enzyme-linked immunosorbent assay (ELISA) titers for desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3) autoantibodies may be helpful as an adjunct to clinical assessment, since titers may correlate with disease activity [<a href="#rid16">16-20</a>]. However, the correlation is not perfect, and ELISA results must be interpreted carefully. (See  <a class="medical medical_review" href="/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus", section on 'Enzyme-linked immunosorbent assay'</a>.)</p><p class="headingAnchor" id="H73755042"><span class="h1">INITIAL THERAPY</span><span class="headingEndMark"> — </span>Systemic glucocorticoids play a central role in the treatment of pemphigus due to the high efficacy of these agents for achieving rapid control of the disease (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>) [<a href="#rid13">13,21</a>]. The major approaches to initial treatment are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> and systemic glucocorticoid therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic glucocorticoid therapy with the concurrent or subsequent addition of an adjuvant therapy (typically <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>)</p><p></p><p>Systemic glucocorticoid monotherapy is an alternative approach that can be effective for some patients. However, due to the potential serious adverse effects of long-term treatment with high doses of systemic glucocorticoids, combination therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or adjuvant conventional immunosuppressive therapy is generally preferred, particularly for patients with increased risk for complications of prolonged (&gt;4 months) glucocorticoid therapy [<a href="#rid14">14</a>]. In addition, in patients with moderate to severe pemphigus, the combination of rituximab and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> appears to be more effective than prednisone monotherapy [<a href="#rid15">15</a>]. (See <a class="local">'Selection of primary therapy'</a> below and <a class="local">'Rituximab and systemic glucocorticoids'</a> below and <a class="local">'Systemic glucocorticoids and adjuvant immunosuppressive therapy'</a> below.)</p><p class="headingAnchor" id="H806899198"><span class="h2">Selection of primary therapy</span><span class="headingEndMark"> — </span>Combination therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is our preferred initial approach to pemphigus (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). When rituximab therapy is not feasible, we treat with prednisone and adjuvant <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. The high cost of rituximab can limit the use of rituximab in some settings.</p><p>Our approach is based upon the following considerations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong><strong> plus </strong><strong>prednisone</strong><strong> versus </strong><strong>prednisone</strong><strong> alone </strong>– <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is preferred over prednisone monotherapy based upon a randomized trial that supports a greater likelihood of achieving complete remission off therapy and a lower likelihood of severe adverse events in patients with moderate to severe pemphigus [<a href="#rid15">15</a>]. (See <a class="local">'Rituximab and systemic glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong><strong> plus </strong><strong>prednisone</strong><strong> versus </strong><strong>prednisone</strong><strong> plus </strong><strong>mycophenolate</strong><strong> mofetil or </strong><strong>azathioprine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> plus <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is preferred over prednisone plus <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil based upon a randomized trial that supports a higher likelihood of achieving sustained complete remission, lower dependence on oral glucocorticoids, and reduced disease flares in patients with moderate to severe pemphigus [<a href="#rid22">22</a>]. Of note, serious adverse events occurred in a slightly higher proportion of patients treated with rituximab [<a href="#rid22">22</a>]. (See <a class="local">'Rituximab and systemic glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> has not been directly compared with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. However, a network meta-analysis suggests a greater likelihood of disease remission and lower cumulative glucocorticoid doses with rituximab therapy [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisone</strong><strong> plus </strong><strong>mycophenolate</strong><strong> mofetil versus </strong><strong>prednisone</strong><strong> plus </strong><strong>azathioprine</strong><strong> versus </strong><strong>prednisone</strong><strong> alone </strong>– <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> are employed as glucocorticoid-sparing therapies. Clinician familiarity and comfort with use of mycophenolate mofetil and azathioprine and consideration of drug adverse effect profiles typically guide selection between these drugs. The broader serious adverse effect profile and greater complexity of dosing of azathioprine prompt us to choose mycophenolate mofetil over azathioprine in most cases.</p><p></p><p class="bulletIndent1">However, in a network meta-analysis that compared adjuvant therapies for pemphigus, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> yielded lower cumulative glucocorticoid doses compared with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, suggesting a greater glucocorticoid-sparing effect for azathioprine [<a href="#rid23">23</a>]. Glucocorticoid-sparing effects of mycophenolate mofetil were unconfirmed. In regards to remission, the network meta-analysis did not identify statistically significant differences in achievement of disease remission between mycophenolate mofetil and azathioprine or between adjuvant therapy with these agents and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> monotherapy [<a href="#rid23">23</a>]. (See <a class="local">'Adjuvant conventional immunosuppressive therapies'</a> below.)</p><p></p><p>Alternative approaches have also been proposed [<a href="#rid24">24</a>]. In addition to the option of initial therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and/or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for pemphigus of any severity, the 2020 European S2K guidelines describe oral <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> plus topical corticosteroid and topical corticosteroid monotherapy as options for the initial treatment of mild pemphigus foliaceus (pemphigus foliaceus involving &lt;5 percent of the total body surface area) [<a href="#rid24">24</a>]. However, superiority of this approach has not been proven, and dapsone treatment may be insufficient in a significant proportion of patients [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H4029816880"><span class="h2">Rituximab and systemic glucocorticoids</span></p><p class="headingAnchor" id="H1997764276"><span class="h3">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is given via intravenous infusion. Systemic glucocorticoids are typically given orally. For practical reasons related to obtaining and administering rituximab, glucocorticoid therapy often begins before rituximab therapy. Initial signs of clinical improvement related to systemic glucocorticoid therapy usually become evident within two to three weeks. Effects of rituximab may not appear for 8 to 12 weeks (see <a class="local">'Systemic glucocorticoids'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong><strong> </strong>– The therapeutic regimen for <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> involves two initial infusions followed by periodic maintenance doses, as needed. Typical initial dosing is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two 1000 mg intravenous infusions separated by two weeks [<a href="#rid26">26</a>]</p><p></p><p class="bulletIndent1">Intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (100 mg) or an equivalent glucocorticoid should be given 30 minutes prior to each <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> infusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> – Systemic glucocorticoid therapy typically consists of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a>). Initial doses range from 0.5 to 1.5 mg/kg per day [<a href="#rid14">14</a>]. Our typical initial prednisone regimen is based upon disease severity:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild pemphigus </strong>– 0.5 mg/kg per day</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe pemphigus </strong>– 1 mg/kg per day</p><p></p><p class="bulletIndent1">Clinical characteristics supportive of mild pemphigus include &lt;5 percent total body surface area involvement, no oral lesions, or limited oral lesions that do not impair food intake or require analgesics [<a href="#rid24">24</a>]. Clinical characteristics supportive of moderate to severe pemphigus include involvement of multiple mucosal sites, severe oral lesions or dysphasia with weight loss, significant pain, or ≥5 percent total body surface area involvement [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H2461828193"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Combination therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is an effective initial treatment [<a href="#rid15">15,23</a>]. The most robust data regarding use of rituximab as an initial treatment for pemphigus come from a prospective, open-label, randomized trial:</p><p class="bulletIndent1"><span class="glyph">●</span>In a trial, 90 patients with newly diagnosed, moderate to severe pemphigus vulgaris or pemphigus foliaceus were randomly assigned to either intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (1000 mg on days 1 and 14, then 500 mg at months 12 and 18) <strong>plus</strong> oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (0.5 mg/kg per day for moderate disease and 1 mg/kg per day for severe disease) tapered over three to six months <strong>or</strong> prednisone alone (1 mg/kg per day for moderate disease and 1.5 mg/kg per day for severe disease) tapered over 12 to 18 months [<a href="#rid15">15</a>]. At month 24, 41 of 46 patients (89 percent) in the rituximab plus prednisone group were in complete remission off therapy compared with 15 of 44 patients (34 percent) in the prednisone only group (absolute difference 55 percentage points, 95% CI 38-72). In addition, the rituximab plus prednisone group had a shorter median delay to achieve complete remission off therapy (277 versus 677 days) and less frequent severe adverse events compared with the prednisone only group.</p><p></p><p>In addition, a randomized trial that compared <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (both given in conjunction with systemic glucocorticoids) supports greater benefit of rituximab [<a href="#rid22">22</a>]. (See <a class="local">'Mycophenolate mofetil'</a> below.)</p><p>The results of a population-based, retrospective cohort study suggest that <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy for pemphigus may also be associated with reduced risk for certain long-term cardiovascular and metabolic adverse events when compared with conventional immunosuppressant therapy [<a href="#rid27">27</a>]. The study utilized a computerized database to compare a total of 1602 patients with pemphigus and either a history of rituximab therapy or a history of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil therapy. Patients treated with rituximab had lower risk for myocardial infarction (risk ratio [RR] 0.45, 95% CI 0.24-0.85), stroke (RR 0.42, 95% CI 0.26-0.69), peripheral vascular disease (RR 0.47, 95% CI 0.28-0.79), hypertension (RR 0.48, 95% CI 0.38-0.63), hyperlipidemia (RR 0.45, 95% CI 0.32-0.64), type 2 diabetes (RR 0.63, 95% CI 0.51-0.77), obesity (RR 0.49, 95% CI 0.34-0.72), and osteoporosis (RR 0.46, 95% CI 0.30-0.71). Proposed rationales for reduced risk included reduced systemic glucocorticoid exposure (not specifically assessed in this study) and a potential inhibitory effect of rituximab on atherosclerotic and cardiovascular disease. A statistically significant difference in all-cause mortality was not detected.</p><p>Successful use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> as a single initial agent is also described in case reports and retrospective studies [<a href="#rid28">28-31</a>]. Randomized trials are needed to clarify the efficacy and safety of this approach to treatment.</p><p class="headingAnchor" id="H302739406"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Major risks of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> include infusion reactions and infections. The adverse effects of rituximab and systemic glucocorticoids are reviewed in greater detail separately. Of note, progressive multifocal leukoencephalopathy has been reported in patients treated with rituximab for other indications [<a href="#rid32">32,33</a>]. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H950301"><span class="h2">Systemic glucocorticoids and adjuvant immunosuppressive therapy</span><span class="headingEndMark"> — </span>Treatment with a systemic glucocorticoid and an adjuvant immunomodulatory agent is an alternative to <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and systemic glucocorticoid therapy (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Systemic glucocorticoid therapy is typically started immediately. Adjuvant conventional immunosuppressive drugs (typically <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) are typically prescribed concurrently or shortly after the start of glucocorticoid therapy. (See <a class="local">'Adjuvant conventional immunosuppressive therapies'</a> below.)</p><p class="headingAnchor" id="H1074161322"><span class="h3">Systemic glucocorticoids</span></p><p class="headingAnchor" id="H950662"><span class="h4">Administration</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a>) is the typical mode of glucocorticoid administration for pemphigus [<a href="#rid14">14</a>]. In most patients, systemic glucocorticoid therapy leads to cessation of blistering within two to three weeks and full disease control within six to eight weeks [<a href="#rid34">34</a>].</p><p>The initial dose for <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> is generally 0.5 to 1.5 mg/kg per day [<a href="#rid14">14</a>]. Our typical regimen is [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild pemphigus </strong>– 0.5 to 1 mg/kg per day</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe pemphigus </strong>– 1 to 1.5 mg/kg per day</p><p></p><p>Clinical characteristics supportive of mild pemphigus include &lt;5 percent total body surface area involvement, no oral lesions, or limited oral lesions that do not impair food intake or require analgesics [<a href="#rid24">24</a>]. Clinical characteristics supportive of moderate to severe pemphigus include involvement of multiple mucosal sites, severe oral lesions or dysphasia with weight loss, significant pain, or ≥5 percent total body surface area involvement [<a href="#rid24">24</a>].</p><p>Intravenous pulsed glucocorticoids have also been utilized for the treatment of pemphigus vulgaris but are not proven to be superior to oral therapy and are typically reserved for refractory disease [<a href="#rid14">14</a>]. Treatment regimens have varied widely, and data comparing regimens that incorporate intravenous or oral pulsed glucocorticoids with regimens that do not include pulsed glucocorticoids are limited to a few small studies that have [<a href="#rid35">35,36</a>] or have not [<a href="#rid37">37</a>] demonstrated benefits over various nonpulsed regimens.</p><p class="headingAnchor" id="H3468533042"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Support for the use of systemic glucocorticoids as a primary treatment for pemphigus stems from randomized trials and other studies that have documented improvement in pemphigus with glucocorticoid monotherapy in the majority of patients and from extensive clinical experience with this treatment [<a href="#rid38">38-41</a>]. As an example, in a randomized, open-label trial in which 30 patients with pemphigus vulgaris were treated with <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> alone (2 mg/kg per day), 23 of these patients (77 percent) responded to treatment, and the average time to cessation of blistering was 18 days [<a href="#rid38">38</a>].</p><p>The dramatic fall in mortality from pemphigus observed after the introduction of systemic glucocorticoid therapy also supports the value of systemic glucocorticoid therapy for this indication. (See <a class="local">'Rationale for treatment'</a> above.)</p><p class="headingAnchor" id="H950676"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Adverse effects, such as hypertension, hyperlipidemia, diabetes mellitus, osteoporosis, increased susceptibility to infections, gastrointestinal ulcers, and aseptic bone necrosis, may cause significant morbidity and mortality among patients who receive prolonged systemic glucocorticoid therapy. Frequent patient follow-up and the implementation of appropriate preventive and therapeutic measures for glucocorticoid-related adverse effects are essential. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H950683"><span class="h3">Adjuvant conventional immunosuppressive therapies</span><span class="headingEndMark"> — </span>The major rationale for adjuvant immunosuppressive therapy is a glucocorticoid-sparing effect rather than a direct disease-modifying effect [<a href="#rid42">42</a>]. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are the principal adjuvant immunosuppressive agents for the initial management of pemphigus. Although there is more evidence to support a glucocorticoid-sparing effect of azathioprine, the more favorable side effect profile and ease of administration of mycophenolate mofetil contributes to the frequent use of mycophenolate mofetil. (See <a class="local">'Azathioprine'</a> below and <a class="local">'Mycophenolate mofetil'</a> below.)</p><p class="headingAnchor" id="H950691"><span class="h4">Azathioprine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration </strong>– The level of activity of thiopurine methyltransferase (TPMT), an enzyme involved in the degradation of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> to inactive metabolites, influences dosing of azathioprine. Reduced TPMT activity is associated with an increased risk for azathioprine-induced myelosuppression [<a href="#rid43">43,44</a>]. TPMT activity may be assessed through testing for the level of enzyme activity or genotyping (see  <a class="medical medical_review" href="/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease", section on 'Introduction'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reduced dosing is advised for patients with intermediate or low TPMT activity. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> therapy is <strong>not</strong> recommended for patients with absent TPMT activity [<a href="#rid14">14,24</a>]. (See  <a class="medical medical_review" href="/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent2">Typical dosing is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>High TPMT activity</strong> – Up to 2.5 mg/kg (ideal body weight) per day.</p><p></p><p class="bulletIndent3">We typically begin treatment with 1 mg/kg (ideal body weight) per day of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. We increase the dose by increments of 0.5 mg/kg to reach a maintenance dose of 2.5 mg/kg per day within two to three weeks, provided serious toxicity is not detected.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Intermediate or low TPMT activity </strong>– Lower initial doses and maintenance doses (maintenance dose up to 0.5 to 1.5 mg/kg per day [ideal body weight] depending on level of enzyme activity). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TPMT testing is particularly important in populations with an elevated risk for TPMT polymorphisms [<a href="#rid14">14</a>]. An initial dose of 50 mg per day with close monitoring for adverse effects has been suggested when TPMT testing is not performed in <strong>low-risk</strong> populations [<a href="#rid14">14</a>]. The dose may be gradually titrated upwards, as tolerated, up to 2.5 mg/kg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Randomized trials that evaluated the glucocorticoid-sparing effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> have found conflicting results. A network meta-analysis of randomized trials comparing glucocorticoid-sparing adjuvants in patients with pemphigus supports the ability of azathioprine to reduce cumulative glucocorticoid doses compared with glucocorticoid monotherapy (cumulative glucocorticoid dose mean difference -3023 mg, 95% CI -4701 to -1364 mg) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">Examples of individual trials comparing systemic glucocorticoids and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> with systemic glucocorticoids alone include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized, open-label trial of 120 patients with pemphigus vulgaris that compared four treatment regimens in which <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> (2 mg/kg per day up to a maximum of 120 mg per day followed by a taper) was given alone or in conjunction with another immunosuppressive agent supported the glucocorticoid-sparing effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2.5 mg/kg per day for two months then 50 mg per day) [<a href="#rid38">38</a>]. After one year, patients who received combination therapy with prednisolone and azathioprine had a significantly lower mean total dose of prednisolone than patients treated with prednisolone alone (7712 versus 11,631 mg). However, clinical outcomes were similar in the two groups. After one year, complete remission was attained by 77 percent of patients in the prednisolone-only group and 80 percent of patients who received combination therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 12-month, randomized trial in which 56 patients with a new diagnosis of pemphigus vulgaris were treated with <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> (2 mg/kg per day up to 120 mg per day followed by a taper) plus <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (2.5 mg/kg per day) or prednisolone in a similar regimen plus a placebo pill, patients in both groups achieved statistically significant clinical improvement. A nonsignificant trend towards a lower mean disease activity score was detected in the combination therapy group at each monthly assessment during the last six months of the trial [<a href="#rid39">39</a>]. This difference achieved statistical significance when data from the last three months of therapy were jointly assessed. In contrast to the trial above, a significant difference in the mean total dose of prednisolone was not detected.</p><p></p><p class="bulletIndent1">A 2011 systematic review and meta-analysis of randomized trials published prior to 2009 supports superior glucocorticoid-sparing effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> compared with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil based upon the meta-analysis of two randomized trials (one of which did not find a statistically significant difference in glucocorticoid-sparing effects) [<a href="#rid10">10</a>]. A subsequent network meta-analysis also supports this finding (cumulative glucocorticoid dose mean difference -2302 mg, 95% CI -3640 to -964 mg) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Due to a risk for myelosuppression, close laboratory monitoring is necessary for patients treated with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. We monitor a complete blood count with differential, renal function tests, and liver function tests at baseline, every two weeks for the first three months, and periodically (every two to three months) thereafter.</p><p></p><p class="bulletIndent1">In addition<strong> </strong>to myelosuppression, malignancy, gastrointestinal disorders, and infections are potential adverse effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> therapy. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H950720"><span class="h4">Mycophenolate mofetil</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Doses of 2 g per day (taken as 1 g twice daily) are typically used when <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil is added to systemic glucocorticoid therapy in adults. Enteric-coated mycophenolate sodium is an alternative form of mycophenolate that is given to adults in a dose of 720 mg twice daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A beneficial effect of adjuvant <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil on the likelihood that patients will respond to glucocorticoid treatment has not been demonstrated in randomized trials [<a href="#rid38">38,40,41</a>]. One trial found that adjuvant mycophenolate mofetil was associated with a longer duration of clinical remission [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">A few randomized trials have evaluated the effects of adjuvant treatment with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil on glucocorticoid requirements and patient outcomes, with conflicting results. Although two randomized trials found a statistically significant reduction in glucocorticoid consumption in patients who received adjuvant mycophenolate mofetil compared with patients treated with a glucocorticoid alone [<a href="#rid38">38,40</a>], another randomized trial failed to find a significant glucocorticoid-sparing effect [<a href="#rid41">41</a>]. A network meta-analysis of randomized trials did not confirm a glucocorticoid-sparing effect [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> has been compared with other therapies. A meta-analysis of two randomized trials that compared the glucocorticoid-sparing effects of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and mycophenolate mofetil found that mycophenolate mofetil appeared to have inferior glucocorticoid-sparing effects [<a href="#rid10">10</a>]. (See <a class="local">'Azathioprine'</a> above.)</p><p></p><p class="bulletIndent1">Compared with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil appears to be less effective and to have inferior glucocorticoid-sparing effects but may have a slightly lower risk for severe adverse effects [<a href="#rid22">22</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a trial, 135 patients with moderate to severe pemphigus vulgaris were randomly assigned to receive either intravenous <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (1000 mg on days 1, 15, 168, and 182) or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (1 g per day increased to 2 g per day by week 2) [<a href="#rid22">22</a>]. All patients also received an oral glucocorticoid (1 to 1.5 mg/kg per day) with the goal of discontinuation of the glucocorticoid by week 24. The 125 patients who received at least one dose of trial medication were included in the efficacy analysis. At week 52, 40 percent of patients (25 of 62) in the rituximab group achieved sustained complete remission compared with 10 percent of patients (6 of 63) in the mycophenolate mofetil group. In addition, patients in the rituximab group had a lower mean cumulative dose of oral glucocorticoids (3545 versus 5140 mg) and fewer disease flares (6 versus 44 disease flares). Serious adverse events occurred in 15 of 67 patients (22 percent) in the rituximab group compared with 10 of 68 patients (15 percent) in the mycophenolate mofetil group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are gastrointestinal complaints. Enteric-coated mycophenolate sodium may have some benefit for patient tolerance while maintaining the immunosuppressive effects [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">Pancytopenia is another important side effect of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>. A complete blood count with differential can be obtained at baseline and every two weeks during the first two to three months of therapy, then once monthly within the first year, and every three months thereafter [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">Renal function tests and liver function tests can be obtained at baseline, after one month, and periodically thereafter. Side effects of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are reviewed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H2735797860"><span class="h1">AFTER ACHIEVEMENT OF DISEASE CONTROL</span><span class="headingEndMark"> — </span>Once disease activity has been under control (cessation of new blister formation and established lesions beginning to heal) for a minimum of two weeks and approximately 80 percent of lesions have healed, glucocorticoid tapering should begin, with the goal of reaching the lowest dose needed to keep the disease under control (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>) [<a href="#rid14">14</a>]. The ultimate goal is to withdraw all treatment. Tapering of adjuvant conventional immunosuppressive therapies can begin after the cessation of systemic glucocorticoids (see <a class="local">'Assessing the response to therapy'</a> above and <a class="local">'Adjuvant conventional immunosuppressive therapies'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering of systemic glucocorticoids</strong> – The optimal method of tapering glucocorticoids in patients with pemphigus has not been determined. Thus, approaches to glucocorticoid tapering vary [<a href="#rid11">11,24</a>]. Our approach for a 70 kg adult is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Once no new lesions have formed for seven days, we reduce <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> from 1 mg/kg per day to 0.75 mg/kg per day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <strong>at least seven days</strong> have elapsed since the first dose reduction and no new lesions have formed, we reduce the dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to 0.5 mg/kg per day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If <strong>at least 14 days</strong> have elapsed since the reduction to 0.5 mg/kg per day and no new lesions have formed for at least one week, we reduce the dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to 30 mg per day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thereafter, we continue dose reductions in a stepwise manner with at least 14 days between each reduction and continue the requirement that no new lesions form within seven days prior to the next reduction. Our dose reduction series is as follows: 30, 25, 20, 15, 10, 7.5, 5, 2.5, and 0 mg per day.</p><p></p><p class="bulletIndent1">Other experts have suggested tapering <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> by 25 percent every <strong>two weeks</strong> until a dose of 20 mg per day, then decreasing by 2.5 mg per <strong>week</strong> until a dose of 10 mg per day, and decreasing by 1 mg per <strong>day</strong> thereafter [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering of adjunctive therapy</strong> – The best approach to tapering adjuvant therapy is unclear. We continue adjuvant therapy with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> until at least three months after <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> has been completely and successfully discontinued. Then, we begin to reduce the dose of the adjuvant medication. We reduce azathioprine by 50 mg every eight weeks, mycophenolate mofetil by 500 mg every eight weeks, or mycophenolate sodium by 360 mg every eight weeks until treatment cessation. Some clinicians continue full-dose adjuvant therapy for a longer period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong><strong> maintenance dosing</strong> – Repetition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy has been proposed as a method to maintain remission. However, the indications, efficacy, and most appropriate regimen for this approach remain unclear. The US Food and Drug Administration (FDA) package insert supports 500 mg given at month 12 and every 6 months thereafter or based on clinical evaluation. The 2020 European S2K guidelines suggest that patients in clinical remission who initially presented with severe pemphigus and/or had high levels of anti-desmoglein (Dsg) antibodies three months after administration of rituximab are potential candidates for a 500 or 1000 mg infusion of rituximab at month 6 [<a href="#rid24">24</a>]. In a randomized trial that compared rituximab and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and prednisone, patients in the rituximab group were routinely given a repeat course of rituximab (two 1000 mg doses separated by two weeks) at month 6 [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H1967236690"><span class="h1">MANAGEMENT OF RELAPSES</span><span class="headingEndMark"> — </span>Relapses of pemphigus may be defined as the appearance of three or more new lesions in a month that do not heal spontaneously within one week or by the extension of established lesions in a patient who has achieved disease control [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who received </strong><strong>rituximab</strong><strong> as initial treatment</strong> – Relapses that occur during tapering of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, but more than four to six months after the last dose of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, may be treated with a repeat 2 g cycle of rituximab (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>) [<a href="#rid24">24</a>]. In addition, the dose of prednisone can be increased to regain faster disease control (eg, to the second-to-last prednisone dose that controlled disease).</p><p></p><p class="bulletIndent1">Relapses that occur during <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> tapering, but prior to four to six months after the last dose of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, can be managed with a return to the second-to-last dose of prednisone, with the goal of regaining disease control within two weeks [<a href="#rid14">14</a>]. If disease control is not achieved within two weeks, prednisone can be increased to the initial dose.</p><p></p><p class="bulletIndent1">Upon achievement of stable disease control for at least two weeks, tapering of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> can be reattempted. An immunosuppressant (eg, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) may be added for patients in whom successful tapering of prednisone is difficult.</p><p></p><p class="bulletIndent1">Relapses that occur after cessation of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> are managed on a case-by-case basis, with a return to initial treatment regimens or modulation of therapy based upon severity. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1">Patients who do not improve with this approach or experience recurrent relapses may benefit from therapies for refractory pemphigus. (See  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who did not receive </strong><strong>rituximab</strong><strong> as initial treatment</strong> – If relapse occurs during <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> tapering and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy is feasible, patients can be treated with a standard 2 g cycle of rituximab (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy is not feasible and relapse occurs during <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> tapering, the prednisone dose should be increased to the second-to-last dose prior to relapse until control of disease is achieved within two weeks [<a href="#rid14">14</a>]. If patients do not achieve disease control with this intervention, changing to a different oral immunosuppressant should be attempted (eg, from <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil to <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or vice versa) [<a href="#rid14">14</a>]. An oral immunosuppressant should be added for patients receiving systemic glucocorticoid monotherapy [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Upon achievement of stable disease control for at least two weeks, tapering of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> can be reattempted.</p><p></p><p class="bulletIndent1">Patients who are refractory to this approach or experience recurrent relapses may benefit from <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or other therapies for refractory disease. (See  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p></p><p class="headingAnchor" id="H4085696785"><span class="h1">FAILURE TO ACHIEVE DISEASE CONTROL</span><span class="headingEndMark"> — </span>Patients for whom initial therapy does not result in disease control within one month require escalation of therapy (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Options include [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increase dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> up to 1.5 mg/kg per day</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Add <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (if not already received)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Add <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (if <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is not feasible and patient is not already on one of these therapies)</p><p></p><p>When these measures are insufficient, patients may benefit from therapies reserved for refractory disease. The management of pemphigus vulgaris and pemphigus foliaceus that are refractory to initial therapy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p class="headingAnchor" id="H768659593"><span class="h1">OTHER ADJUVANT THERAPIES</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are the mainstays of adjuvant therapy for pemphigus, other therapies are occasionally utilized. Efficacy data for these interventions are limited.</p><p class="headingAnchor" id="H73755079"><span class="h2">Dapsone</span><span class="headingEndMark"> — </span>Based upon reports of efficacy in some patients and the favorable status of <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> as a nonimmunosuppressive therapy [<a href="#rid25">25,47-53</a>], some clinicians choose to use dapsone as an adjuvant therapy in patients with pemphigus, particularly for patients with pemphigus foliaceus or IgA pemphigus:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Target doses for <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> for pemphigus range from 50 to 200 mg per day. Treatment is usually initiated at a low dose (eg, 25 or 50 mg per day in adults) and titrated upward as tolerated. The maximum dose is considered 1.5 mg/kg or 250 mg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A 2009 review of case reports and case series identified 37 patients with pemphigus vulgaris and 18 patients with pemphigus foliaceus who were treated with <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> (50 to 300 mg per day) with or without <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or other immunosuppressive therapies [<a href="#rid47">47</a>]. Responses to dapsone were documented in 86 percent of the patients with pemphigus vulgaris and 78 percent of the patients with pemphigus foliaceus. The responders included 6 of 6 patients with pemphigus vulgaris and 9 of 14 patients with pemphigus foliaceus who received dapsone as monotherapy.</p><p></p><p class="bulletIndent1">A subsequent, small, randomized trial that evaluated the efficacy of adjuvant <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> (150 to 200 mg per day) for facilitating the tapering of systemic glucocorticoids in patients with pemphigus vulgaris that was well controlled with a systemic glucocorticoid (with or without an adjuvant immunosuppressant), but refractory to glucocorticoid tapering, failed to find a statistically significant effect [<a href="#rid48">48</a>]. A reduction in the dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to less than 7.5 mg per day was achieved within one year in 5 of 9 patients (56 percent) treated with adjuvant dapsone and 3 of 10 patients (30 percent) who received a placebo pill instead of dapsone as adjuvant therapy.</p><p></p><p class="bulletIndent1">Monotherapy with relatively high doses of <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> (200 to 300 mg per day) appeared to be effective as an initial treatment for pemphigus foliaceus in a small series [<a href="#rid25">25</a>]. Five of the nine patients had at least a 50 percent reduction in the extent of the disease within 15 days. However, four patients failed to respond to dapsone treatment, three patients required discontinuation of therapy, one patient ceased treatment due to toxic hepatitis and hemolytic anemia, and two patients ceased treatment due to methemoglobinemia. Additional studies are necessary to determine the role of dapsone in the treatment of pemphigus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Hemolysis is an expected side effect of <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> that occurs, to some degree, in all treated patients. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an elevated risk for severe hemolytic anemia related to dapsone therapy. Thus, we evaluate patients for G6PD deficiency prior to the initiation of dapsone. (See  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p></p><p class="bulletIndent1">Additional adverse effects of <a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">dapsone</a> include methemoglobinemia, agranulocytosis, hypersensitivity, and motor neuropathy. Close hematologic monitoring for hemolysis and agranulocytosis is essential during treatment.</p><p></p><p class="headingAnchor" id="H73755086"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Other drugs that have been used as adjuvants to systemic glucocorticoids for pemphigus are <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and combination therapy with a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative and <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong><strong> </strong>– No randomized trials have evaluated the efficacy of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> as an adjuvant therapy. Support for this drug is derived from uncontrolled studies and case series [<a href="#rid54">54-56</a>]. Typical dosing is 10 to 25 mg per <strong>week</strong>.</p><p></p><p class="bulletIndent1">In a retrospective study of 23 patients with pemphigus vulgaris for whom <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (up to 15 to 25 mg per week) was added to systemic glucocorticoid therapy, 21 patients (91 percent) had improvement in blistering after the addition of methotrexate, and 16 patients (70 percent) were eventually able to discontinue <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> completely (mean time to discontinuation of prednisone therapy 18 months) [<a href="#rid56">56</a>]. In a separate case series, six of nine patients treated with adjuvant methotrexate (10 to 17.5 mg per week) for pemphigus vulgaris were able to discontinue prednisone within six months [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong><strong> </strong>– Although efficacy of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> was reported in case series of patients with pemphigus [<a href="#rid58">58,59</a>], two randomized trials did not demonstrate an advantage of cyclosporine therapy [<a href="#rid60">60,61</a>]. Dosing for cyclosporine is 2.5 to 5 mg/kg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tetracyclines and </strong><strong>nicotinamide</strong><strong> </strong>– Limited data from retrospective studies suggest that combination therapy with a <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative (eg, tetracycline, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>) and <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> (also known as niacinamide), a well-tolerated regimen often used for bullous pemphigoid, may be a useful adjuvant to systemic glucocorticoid therapy for pemphigus [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1">The typical adult dose for <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> is 500 mg four times daily. <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> and <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> are given as 100 mg twice daily, and <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> is usually given as 500 mg three times per day. Of note, a small, uncontrolled, prospective study found poor treatment results when tetracycline and nicotinamide were given as the primary therapeutic regimen for pemphigus rather than as a glucocorticoid-sparing therapy [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">Successful treatment of pemphigus vegetans (a rare variant of pemphigus vulgaris) with only <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> is documented in a case report [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H73755107"><span class="h1">SUPPORTIVE CARE</span></p><p class="headingAnchor" id="H86495080"><span class="h2">Skin care</span><span class="headingEndMark"> — </span>Local skin care measures may help to improve patient comfort and reduce the risk for infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blister and wound care</strong> – Clinicians or patients should puncture and drain large blisters in a sterile manner. The epithelial roof of the blister should be left intact after draining to serve as wound covering and to reduce the risk for infection.</p><p></p><p class="bulletIndent1">Wound areas should be kept clean to reduce the risk for infection. Erosions may be covered with antibiotic ointment or a bland emollient (eg, petrolatum), with or without a nonadhesive wound dressing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent lesions</strong> – In our experience, twice-daily application of a high-potency topical corticosteroid (eg, <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> propionate ointment or gel) directly to erosions can be a useful adjunct to systemic therapy for persistent, active, hard-to-treat pemphigus lesions [<a href="#rid1">1</a>]. Intralesional injection of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide (20 mg/mL) may also help to heal persistent lesions [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recognition and prevention of secondary infection</strong> – Patients should be informed about the warning signs of infection (eg, purulence, crusting, worsening pain, fever) to facilitate prompt diagnosis and early treatment.</p><p></p><p class="bulletIndent1">The possibility of secondary infection (particularly herpes simplex virus infection) should be considered for lesions that fail to respond as expected to therapy, and infection should be treated appropriately if detected [<a href="#rid1">1,66,67</a>]. Due to the inhibitory effects of herpes simplex virus infection on healing of skin lesions in patients with pemphigus, we often initiate prophylactic antiviral therapy after an episode of pemphigus complicated by herpes simplex infection. (See  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H73755246"><span class="h2">Management of oral symptoms</span><span class="headingEndMark"> — </span>Oral mucosal involvement in pemphigus vulgaris causes discomfort, which may be severe.</p><p>In addition to treatment of the disease process with systemic therapy, we have found the following measures useful for reducing symptoms during active disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance of spicy, sharp, abrasive, or very hot foods.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Application of topical anesthetics as needed (eg, viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> 2% solution, lidocaine 2% gel).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral hygiene (teeth should be brushed twice daily with a soft-bristle brush with a bland toothpaste and flossed daily; additionally, professional dental cleanings may be of use).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical anti-inflammatory therapies</strong> – In our experience, topical corticosteroids help to improve oral symptoms of pemphigus in some patients. We often utilize a medium- or high-potency topical corticosteroid (eg, <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> 0.1% in dental paste or <a class="drug drug_general" data-topicid="8460" href="/d/drug information/8460.html" rel="external">fluocinonide</a> 0.05% gel applied with gauze occlusion) or a corticosteroid mouthwash (eg, 5 mL of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 0.5 mg/5 mL solution as a mouth rinse) two to three times per day. We have also found topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment useful. Patients may find topical anesthetics (eg, viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>) helpful for managing symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment of </strong><strong><em>Candida</em></strong><strong> infections</strong> – <em>Candida</em> infection is a common occurrence in patients with mucosal pemphigus vulgaris who are treated with systemic glucocorticoids. We prescribe oral <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">nystatin</a> swish and swallow (or swish and spit) or <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a> lozenges as prophylaxis for patients receiving systemic glucocorticoids or monitor patients closely for the development of oropharyngeal candidal infection and treat if infection develops. (See  <a class="medical medical_review" href="/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H294724408"><span class="h2">Patient support</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pemphigus.org%2F&amp;token=kgWnuLuwd5ywHVQww%2BY9ejelGxqgN19Ljg020%2Fmkv%2B6Jk4iV1n3Xa69uIoeLfYSW&amp;TOPIC_ID=15303" target="_blank">International Pemphigus and Pemphigoid Foundation</a> provides resources for patient support.</p><p class="headingAnchor" id="H507180934"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/132082.html" rel="external">"Society guideline links: Pemphigus"</a>.)</p><p class="headingAnchor" id="H86495636"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease overview </strong>– Pemphigus is defined as a group of autoimmune, blistering disorders that result in intraepithelial blistering in mucous membranes and/or skin (<a class="graphic graphic_picture graphicRef57924 graphicRef53425 graphicRef51868 graphicRef63170 graphicRef60530 graphicRef72419" href="/d/graphic/57924.html" rel="external">picture 1A-D, 2A-B</a>). Pemphigus vulgaris and pemphigus foliaceus are the most common subtypes of pemphigus. (See <a class="local">'Rationale for treatment'</a> above and <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment </strong>– Pemphigus is a potentially life-threatening disorder for which treatment is always indicated. The initial goal of treatment is to induce complete remission while minimizing treatment-related adverse effects. Long-term remission after the discontinuation of therapy is the ultimate goal. The response to treatment is primarily assessed through clinical evaluation. (See <a class="local">'Approach to treatment'</a> above and <a class="local">'Assessing the response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach </strong>– Initial treatment of pemphigus vulgaris and pemphigus foliaceus generally consists of systemic glucocorticoids in conjunction with other immunomodulatory therapies, such as <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Systemic glucocorticoid therapy is useful for achieving rapid disease control. Improved efficacy and/or glucocorticoid-sparing effects are the primary reasons for combination therapy (see <a class="local">'Approach to treatment'</a> above and <a class="local">'Initial therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with pemphigus vulgaris or pemphigus foliaceus, we suggest initial treatment with a combination of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> rather than prednisone alone or prednisone in conjunction with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Randomized trials support greater efficacy of combination therapy with prednisone and rituximab in moderate to severe pemphigus. Indirect evidence suggests that <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> is less effective than rituximab. (See <a class="local">'Selection of primary therapy'</a> above and <a class="local">'Rituximab and systemic glucocorticoids'</a> above.) </p><p></p><p class="bulletIndent2">When <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy is not feasible, an alternative initial approach is <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> and adjuvant <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Selection between azathioprine and mycophenolate mofetil is often based upon clinician comfort with these drugs and consideration of risk for drug-related adverse effects. Although there is more evidence to support a glucocorticoid-sparing effect of azathioprine, the more favorable side effect profile and ease of administration of mycophenolate mofetil contributes to our frequent use of mycophenolate mofetil. (See <a class="local">'Systemic glucocorticoids and adjuvant immunosuppressive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After achievement of disease control </strong>– Once disease activity is under control (cessation of new blister formation and established lesions beginning to heal) for at least two weeks and 80 percent of established lesions have healed, tapering of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> can begin. Tapering of adjuvant immunosuppressive therapies can begin after successful cessation of prednisone. (See <a class="local">'After achievement of disease control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing or refractory disease </strong>– Relapses after achievement of disease control are managed with the resumption of previously effective doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> and/or the addition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or conventional immunosuppressive therapy (<a class="graphic graphic_algorithm graphicRef134326" href="/d/graphic/134326.html" rel="external">algorithm 1</a>). Patients who do not respond to this approach or experience frequent relapses may benefit from therapies for refractory disease. Patients who fail to respond to preferred initial therapies may also benefit from therapies for refractory disease. (See <a class="local">'Management of relapses'</a> above and  <a class="medical medical_review" href="/d/html/15304.html" rel="external">"Management of refractory pemphigus vulgaris and pemphigus foliaceus"</a>.)</p><p></p><p class="bulletIndent1">The possibility of secondary infection (eg, herpes simplex virus infection) should also be considered when individual lesions fail to respond to therapy. (See <a class="local">'Skin care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care </strong>– Cutaneous and mucosal involvement in pemphigus may result in significant pain, functional impairment, and negative effects on quality of life. Skin and wound care measures, interventions to improve oral symptoms, and patient support groups can be beneficial. (See <a class="local">'Supportive care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005; 366:61.</a></li><li><a class="nounderline abstract_t">Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity 2012; 45:7.</a></li><li><a class="nounderline abstract_t">Lever WF. Pemphigus. Medicine (Baltimore) 1953; 32:1.</a></li><li><a class="nounderline abstract_t">Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132:203.</a></li><li><a class="nounderline abstract_t">Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142:1447.</a></li><li><a class="nounderline abstract_t">Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; :CD006263.</a></li><li><a class="nounderline abstract_t">Cirillo N, Cozzani E, Carrozzo M, Grando SA. Urban legends: pemphigus vulgaris. Oral Dis 2012; 18:442.</a></li><li><a class="nounderline abstract_t">Leshem YA, Gdalevich M, Ziv M, et al. Opportunistic infections in patients with pemphigus. J Am Acad Dermatol 2014; 71:284.</a></li><li><a class="nounderline abstract_t">Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol 2005; 44:470.</a></li><li><a class="nounderline abstract_t">Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64:903.</a></li><li><a class="nounderline abstract_t">Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58:1043.</a></li><li><a class="nounderline abstract_t">Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol 2012; 30:84.</a></li><li><a class="nounderline abstract_t">Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177:1170.</a></li><li><a class="nounderline abstract_t">Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol 2020; 82:575.</a></li><li><a class="nounderline abstract_t">Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017; 389:2031.</a></li><li><a class="nounderline abstract_t">Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140:351.</a></li><li><a class="nounderline abstract_t">Cheng SW, Kobayashi M, Kinoshita-Kuroda K, et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147:261.</a></li><li><a class="nounderline abstract_t">Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010; 134:320.</a></li><li><a class="nounderline abstract_t">Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:2010.</a></li><li><a class="nounderline abstract_t">Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145:529.</a></li><li><a class="nounderline abstract_t">Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996; 34:645.</a></li><li><a class="nounderline abstract_t">Werth VP, Joly P, Mimouni D, et al. Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. N Engl J Med 2021; 384:2295.</a></li><li><a class="nounderline abstract_t">Lee MS, Yeh YC, Tu YK, Chan TC. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2021; 85:176.</a></li><li><a class="nounderline abstract_t">Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34:1900.</a></li><li><a class="nounderline abstract_t">Basset N, Guillot B, Michel B, et al. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987; 123:783.</a></li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5450lbl.pdf (Accessed on July 27, 2018).</li><li><a class="nounderline abstract_t">Kridin K, Mruwat N, Ludwig RJ. Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus. JAMA Dermatol 2023; 159:56.</a></li><li><a class="nounderline abstract_t">Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2011; 65:1064.</a></li><li><a class="nounderline abstract_t">Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, et al. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol 2015; 151:200.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. Int Immunopharmacol 2016; 34:25.</a></li><li><a class="nounderline abstract_t">Nili A, Mahmoudi H, Heidari N, et al. Rituximab monotherapy in mild pemphigus. J Dermatolog Treat 2022; 33:1784.</a></li><li><a class="nounderline abstract_t">Chakraborty S, Tarantolo SR, Treves J, et al. Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab. Case Rep Oncol 2011; 4:136.</a></li><li><a class="nounderline abstract_t">Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156.</a></li><li><a class="nounderline abstract_t">Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149:926.</a></li><li><a class="nounderline abstract_t">Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 2002; 16:353.</a></li><li><a class="nounderline abstract_t">Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996; 132:1435.</a></li><li><a class="nounderline abstract_t">Mentink LF, Mackenzie MW, Tóth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006; 142:570.</a></li><li><a class="nounderline abstract_t">Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57:622.</a></li><li><a class="nounderline abstract_t">Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2013; 27:1285.</a></li><li><a class="nounderline abstract_t">Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130:2041.</a></li><li><a class="nounderline abstract_t">Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol 2012; 26:855.</a></li><li><a class="nounderline abstract_t">Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015; 29:405.</a></li><li><a class="nounderline abstract_t">Anstey AV, Wakelin S, Reynolds NJ, British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004; 151:1123.</a></li><li><a class="nounderline abstract_t">Jackson AP, Hall AG, McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 1997; 136:133.</a></li><li><a class="nounderline abstract_t">Sollinger HW, Sundberg AK, Leverson G, et al. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 2010; 89:446.</a></li><li class="breakAll">Perlis C, Pan TD, McDonald CJ. Cytotoxic agents. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.197.</li><li><a class="nounderline abstract_t">Gürcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.</a></li><li><a class="nounderline abstract_t">Werth VP, Fivenson D, Pandya AG, et al. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2008; 144:25.</a></li><li><a class="nounderline abstract_t">Chatterjee M, Meru S, Vasudevan B, et al. Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsone. Indian J Dermatol 2012; 57:495.</a></li><li><a class="nounderline abstract_t">Hirata Y, Abe R, Kikuchi K, et al. Intraepidermal neutrophilic IgA pemphigus successfully treated with dapsone. Eur J Dermatol 2012; 22:282.</a></li><li><a class="nounderline abstract_t">Suzuki M, Karube S, Kobori Y, et al. IgA pemphigus occurring in a 1-month-old infant. J Am Acad Dermatol 2003; 48:S22.</a></li><li><a class="nounderline abstract_t">Gniadecki R, Bygum A, Clemmensen O, et al. IgA pemphigus: the first two Scandinavian cases. Acta Derm Venereol 2002; 82:441.</a></li><li><a class="nounderline abstract_t">Baum S, Debby A, Gilboa S, et al. Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study. Dermatology 2016; 232:578.</a></li><li><a class="nounderline abstract_t">Gürcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161:723.</a></li><li><a class="nounderline abstract_t">Baum S, Greenberger S, Samuelov L, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol 2012; 22:83.</a></li><li><a class="nounderline abstract_t">Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol 2013; 169:916.</a></li><li><a class="nounderline abstract_t">Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999; 135:1275.</a></li><li><a class="nounderline abstract_t">Mobini N, Padilla T Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997; 36:264.</a></li><li><a class="nounderline abstract_t">Vardy DA, Cohen AD. Cyclosporine therapy should be considered for maintenance of remission in patients with pemphigus. Arch Dermatol 2001; 137:505.</a></li><li><a class="nounderline abstract_t">Chrysomallis F, Ioannides D, Teknetzis A, et al. Treatment of oral pemphigus vulgaris. Int J Dermatol 1994; 33:803.</a></li><li><a class="nounderline abstract_t">Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136:868.</a></li><li><a class="nounderline abstract_t">McCarty M, Fivenson D. Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents. J Am Acad Dermatol 2014; 71:475.</a></li><li><a class="nounderline abstract_t">Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 1993; 28:998.</a></li><li><a class="nounderline abstract_t">Alpsoy E, Yilmaz E, Basaran E, et al. Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? Arch Dermatol 1995; 131:1339.</a></li><li><a class="nounderline abstract_t">von Köckritz A, Ständer S, Zeidler C, et al. Successful monotherapy of pemphigus vegetans with minocycline and nicotinamide. J Eur Acad Dermatol Venereol 2017; 31:85.</a></li><li><a class="nounderline abstract_t">Caldarola G, Kneisel A, Hertl M, Feliciani C. Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations. Eur J Dermatol 2008; 18:440.</a></li><li><a class="nounderline abstract_t">Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol 2018; 54:1.</a></li></ol></div><div id="topicVersionRevision">Topic 15303 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15993235" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21939410" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pemphigus autoimmunity: hypotheses and realities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13024494" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pemphigus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629830" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The adjuvant therapy of pemphigus. An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116835" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160272" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Interventions for pemphigus vulgaris and pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22335787" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Urban legends: pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815564" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Opportunistic infections in patients with pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941433" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pemphigus: analysis of 1209 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353333" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339444" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137231" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Current therapy of the pemphigus group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192996" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438767" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and management of pemphigus: Recommendations of an international panel of experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28342637" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233237" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174096" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015693" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257868" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451496" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8601655" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Influence of treatment on the clinical course of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34097368" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32798583" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32830877" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3579359" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dapsone as initial treatment in superficial pemphigus. Report of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3579359" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dapsone as initial treatment in superficial pemphigus. Report of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36449276" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000877" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354242" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919279" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33040641" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rituximab monotherapy in mild pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21691572" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555606" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14632796" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Guidelines for the management of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12224691" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961871" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702494" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17583373" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062214" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410913" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752101" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25338479" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606506" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Guidelines for prescribing azathioprine in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039314" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177347" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177347" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19824739" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18209165" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23248372" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pemphigus foliaceus masquerading as IgA pemphigus and responding to dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378059" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intraepidermal neutrophilic IgA pemphigus successfully treated with dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12582378" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : IgA pemphigus occurring in a 1-month-old infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12575851" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : IgA pemphigus: the first two Scandinavian cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27698327" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19548961" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266247" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772610" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522684" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Methotrexate as an adjuvant treatment for pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039184" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11295940" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cyclosporine therapy should be considered for maintenance of remission in patients with pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7822089" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of oral pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890988" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24906610" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Two decades of using the combination of tetracycline derivatives and niacinamide as steroid-sparing agents in the management of pemphigus: defining a niche for these low toxicity agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496464" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503585" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27600093" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Successful monotherapy of pemphigus vegetans with minocycline and nicotinamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573719" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29313220" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
